A randomized phase II study of perioperative chemotherapy plus bevacizumab versus postoperative chemotherapy plus bevacizumab inpatients with upfront resectable hepatic colorectal metastases (APPROACH).

Authors

You Jin Chun

Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Seoul, Korea, Republic of (South)

You Jin Chun , Seong-Geun Kim , Keun-Wook Lee , Sang Hee Cho , Tae Won Kim , Ji Yeon Baek , Young Suk Park , Soojung Hong , Jee Hung Kim , Seung-Hoon Beom , Minkyu Jung , Sang Joon Shin , Joong Bae Ahn

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2018 Gastrointestinal Cancers Symposium

bookmark_border

Liver and/or lung metastasectomy after cetuximab or bevacizumab+FOLFIRI chemotherapy in patients (pts) with metastatic colorectal cancer (mCRC).

First Author: Sang-A Kim

insert_chart_outlined

Poster

2017 ASCO Annual Meeting

bookmark_border

REsect: Blinded assessment of amenability to potentially curative treatment of previously unresectable colorectal cancer liver metastases (CRC LM) after chemotherapy ± RadioEmbolization (SIRT) in the randomized SIRFLOX trial.

First Author: Benjamin Garlipp

insert_chart_outlined

Poster

2016 ASCO Annual Meeting

bookmark_border

FOLFIRINOX combined to targeted therapy according RAS status for colorectal cancer patients with liver metastases initially non-resectable: A phase II randomized Study—Prodige 14 – accord 21 (METHEP-2), a unicancer GI trial.

First Author: Marc Ychou

insert_chart_outlined

Poster

2020 Gastrointestinal Cancers Symposium

bookmark_border

Outcomes of elderly patients with resectable liver metastases from colorectal cancer (CRLM): Single center experience.

First Author: Laura Mansour